These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 22829710)

  • 1. Expression of Somatostatin Receptor (SSTR) Subtypes (SSTR-1, 2A, 3, 4 and 5) in Neuroendocrine Tumors Using Real-time RT-PCR Method and Immunohistochemistry.
    Mizutani G; Nakanishi Y; Watanabe N; Honma T; Obana Y; Seki T; Ohni S; Nemoto N
    Acta Histochem Cytochem; 2012 Jun; 45(3):167-76. PubMed ID: 22829710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroendocrine neoplasms and somatostatin receptor subtypes expression.
    Hankus J; Tomaszewska R
    Nucl Med Rev Cent East Eur; 2016; 19(2):111-7. PubMed ID: 27479788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms.
    Nielsen K; Binderup T; Langer SW; Kjaer A; Knigge P; Grøndahl V; Melchior L; Federspiel B; Knigge U
    BMC Cancer; 2020 Jan; 20(1):27. PubMed ID: 31924180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancy.
    Kaemmerer D; Träger T; Hoffmeister M; Sipos B; Hommann M; Sänger J; Schulz S; Lupp A
    Oncotarget; 2015 Sep; 6(29):27566-79. PubMed ID: 26259237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathologic characteristics of pancreatic neuroendocrine tumors and relation of somatostatin receptor type 2A to outcomes.
    Okuwaki K; Kida M; Mikami T; Yamauchi H; Imaizumi H; Miyazawa S; Iwai T; Takezawa M; Saegusa M; Watanabe M; Koizumi W
    Cancer; 2013 Dec; 119(23):4094-102. PubMed ID: 24022344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of somatostatin receptor profile of neuroendocrine carcinomas of the breast.
    Kontogeorgos G; Thodou E; Choreftaki T
    Pathol Res Pract; 2020 Sep; 216(9):153066. PubMed ID: 32825939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of somatostatin receptor subtypes in human thyroid tumors: the immunohistochemical and molecular biology (RT-PCR) investigation.
    Pisarek H; Stepień T; Kubiak R; Borkowska E; Pawlikowski M
    Thyroid Res; 2009 Jan; 2(1):1. PubMed ID: 19173713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
    Tang LH; Basturk O; Sue JJ; Klimstra DS
    Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SSTR1 and SSTR5 subtypes are the dominant forms of somatostatin receptor in neuroendocrine tumors.
    Pisarek H; Pawlikowski M; Kunert-Radek J; Kubiak R; Winczyk K
    Folia Histochem Cytobiol; 2010 Jan; 48(1):142-7. PubMed ID: 20529830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment modalities favoring outcome in well-differentiated neuroendocrine tumors G3.
    Hinterleitner M; Pfeiffer R; Trautwein NF; Sipos B; Singer S; Nadalin S; Königsrainer A; Lauer UM; la Fougère C; Zender L; Hinterleitner C
    Front Endocrinol (Lausanne); 2023; 14():1285529. PubMed ID: 38260136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatostatin receptor subtypes in neuroendocrine tumor cell lines and tumor tissues.
    Jonas S; John M; Boese-Landgraf J; Häring R; Prevost G; Thomas F; Rosewicz S; Riecken EO; Wiedenmann B; Neuhaus P
    Langenbecks Arch Chir; 1995; 380(2):90-5. PubMed ID: 7760656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
    Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
    Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of somatostatin receptor 2A immunohistochemistry, RT-qPCR, and in vivo PET/CT data in patients with pancreatic neuroendocrine neoplasm.
    Kaemmerer D; Wirtz RM; Fischer EK; Hommann M; Sänger J; Prasad V; Specht E; Baum RP; Schulz S; Lupp A
    Pancreas; 2015 May; 44(4):648-54. PubMed ID: 25872131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of somatostatin receptor subtype expression in human neuroendocrine tumors using two sets of new monoclonal antibodies.
    Lambertini C; Barzaghi-Rinaudo P; D'Amato L; Schulz S; Nuciforo P; Schmid HA
    Regul Pept; 2013 Nov; 187():35-41. PubMed ID: 24188818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of immunoreactive score, HER2/neu score and H score for the immunohistochemical evaluation of somatostatin receptors in bronchopulmonary neuroendocrine neoplasms.
    Specht E; Kaemmerer D; Sänger J; Wirtz RM; Schulz S; Lupp A
    Histopathology; 2015 Sep; 67(3):368-77. PubMed ID: 25641082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aberrant expression of human achaete-scute homologue gene 1 in the gastrointestinal neuroendocrine carcinomas.
    Shida T; Furuya M; Nikaido T; Kishimoto T; Koda K; Oda K; Nakatani Y; Miyazaki M; Ishikura H
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):450-8. PubMed ID: 15701827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small Cell Carcinomas of the Bladder Highly Express Somatostatin Receptor Type 2A: Impact on Prognosis and Treatment--A Multicenter Study of Urooncology Society, Turkey.
    Neşe N; Kumbaraci BS; Baydar DE; Kiliçaslan I; Sari AA; Şen S; Gönül II; Kankaya D; Özlük Y; Ermete M; Özağari A; Bal N; Kiremitçi S; Yildiz K; Tuna B; Şen N; Yörükoğlu K
    Appl Immunohistochem Mol Morphol; 2016 Apr; 24(4):253-60. PubMed ID: 25906124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroendocrine Breast Carcinomas Share Prognostic Factors with Gastroenteropancreatic Neuroendocrine Tumors: A Putative Prognostic Role of Menin, p27, and SSTR-2A.
    Roininen N; Takala S; Haapasaari KM; Jukkola-Vuorinen A; Mattson J; Heikkilä P; Karihtala P
    Oncology; 2019; 96(3):147-155. PubMed ID: 30282082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential expression of somatostatin receptors 1-5 in neuroendocrine carcinoma of the lung.
    Tsuta K; Wistuba II; Moran CA
    Pathol Res Pract; 2012 Aug; 208(8):470-4. PubMed ID: 22770972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of somatostatin and dopamine 2 receptors in neuroendocrine tumours and the potential role for new biotherapies.
    Srirajaskanthan R; Watkins J; Marelli L; Khan K; Caplin ME
    Neuroendocrinology; 2009; 89(3):308-14. PubMed ID: 19307732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.